Nvidia and Eli Lilly Commit $1 Billion to AI-Powered Drug Discovery Lab in San Francisco

Nvidia and Eli Lilly have announced a major collaboration to establish a first-of-its-kind artificial intelligence co-innovation lab in the San Francisco Bay Area, committing up to $1 billion in investment over the next five years. The partnership was unveiled at the J.P. Morgan Healthcare Conference and aims to dramatically speed up drug discovery and development by combining Nvidia’s cutting-edge AI computing with Lilly’s deep pharmaceutical expertise. 

The new facility will bring together multidisciplinary teams of AI engineers and life-science researchers under one roof, leveraging Nvidia’s BioNeMo AI platform and Vera Rubin architecture chips to generate large-scale biological and chemical data for next-generation AI models. Much of the work will focus on creating systems that tightly integrate computational design with real-world experimentation, allowing continuous learning and faster iteration in identifying